Tcr2 Therapeutics Inc

NASDAQ:TCRR  
1.14
-0.04 (-3.39%)
4:08:29 PM EDT: $1.12 -0.02 (-1.75%)
Earnings Announcements

TCR2 Therapeutics Reports Q3 Loss Of $0.79 Per Share

Published: 11/08/2022 11:56 GMT
Tcr2 Therapeutics Inc (TCRR) - Tcr² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update.
Qtrly Loss per Share $0.79.
Continues to Project Net Cash Use of $115-125 Million for 2022.
Expect Cash on Hand to Support Operations Into 2024.
Q3 Earnings per Share View $-0.83 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.77

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.81

More details on our Analysts Page.